• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长期睾丸癌幸存者的不良健康结局与全球生活质量:30年纵向研究视角

Adverse health outcomes and global quality of life in long-term testicular cancer survivors: a longitudinal 30-year perspective.

作者信息

Fosså S D, Haugnes H S, Dahl A A, Kiserud C E, Fosså A, Skalleberg J, Myklebust T Å

机构信息

Department of Oncology, Oslo University Hospital, Oslo; Institute of Clinical Medicine, University of Oslo, Oslo.

Department of Oncology, University Hospital of North Norway, Tromsø; Department of Clinical Medicine, UiT, The Arctic University, Tromsø.

出版信息

Ann Oncol. 2023 Dec;34(12):1165-1174. doi: 10.1016/j.annonc.2023.09.3101. Epub 2023 Sep 21.

DOI:10.1016/j.annonc.2023.09.3101
PMID:37739265
Abstract

BACKGROUND

The aim of this study was to characterize the prevalence of self-reported adverse health outcomes (AHOs), track changes in AHOs, and examine their impact on health-related quality of life (HrQoL) in testicular cancer survivors (TCSs) who were diagnosed between 1980 and 1994. These assessments were conducted during two survey waves (SWs), with the first occurring ∼12 years after surgery-only or platinum-based chemotherapy (PBCT), and the second ∼28 years after initial treatment. The study primarily focused on 'typical AHOs', which included Peripheral Sensory Neuropathy (PSN), Raynaud's phenomenon, Tinnitus, and Hearing loss.

PATIENTS AND METHODS

A total of 427 TCSs were included in the evaluation, distributed as follows: surgery-only group (n = 155), PBCT-standard group with ≤850 mg cisplatin (n = 222), and PBCT-high group with >850 mg cisplatin (n = 50). For comparison of HrQoL, men from the general population served as a control group (referred to as 'Norms'). The statistical significance level was set at P < 0.05, and clinical importance, in terms of testing HrQoL differences, was defined as Δ ≥2.5 points.

RESULTS

A higher number of TCSs who underwent PBCT reported experiencing typical AHOs compared with those who had surgery only. The highest prevalence rates were observed among TCSs who had undergone PBCT-high. Further, the number of TCSs describing typical AHOs, except Raynaud's phenomenon, increased during the observation period of 16 years. At the last SW, a median of 4 AHOs (any type) were reported after PBCT-high compared with a median of 2 AHOs after Surgery-only or after PBCT-standard. With Surgery-only as reference, PBCT-high, but not PBCT-standard, was associated with decreasing physical HrQoL in the last SW (A2 Regression coefficient: -4.3; P = 0.008). When comparing all TCSs with Norms no clinically important difference in physical and mental HrQoL was observed at either SW. However, at the last SW, TCSs after PBCT-high therapy represented a subgroup of TCSs with clinically important impairment of HRQoL. Of the typical AHOs, only PSN reduced HrQoL. Chronic fatigue, pain, anxiety/depression, sexual dysfunction, unemployment, being single, and low education were additional covariates.

CONCLUSIONS

After a median of 28 years since their treatment, HrQoL in TCSs was found to be comparable to that of Norms. This similarity held true even though AHOs, especially after PBCT-high, were becoming more prevalent among TCSs. The study revealed that individuals with a history of PBCT-high are at a high risk of experiencing a significantly increased prevalence of long-term AHOs, which subsequently leads to diminished HrQoL. It is crucial to recognize and provide specialized attention to these TCSs during lifelong follow-up care.

摘要

背景

本研究的目的是描述自我报告的不良健康结局(AHOs)的发生率,追踪AHOs的变化情况,并研究其对1980年至1994年间确诊的睾丸癌幸存者(TCSs)健康相关生活质量(HrQoL)的影响。这些评估在两个调查波次(SWs)中进行,第一次在仅接受手术或铂类化疗(PBCT)后约12年进行,第二次在初始治疗后约28年进行。该研究主要关注“典型AHOs”,包括周围感觉神经病变(PSN)、雷诺现象、耳鸣和听力损失。

患者与方法

共有427名TCSs纳入评估,分布如下:仅手术组(n = 155)、顺铂剂量≤850 mg的PBCT标准组(n = 222)和顺铂剂量>850 mg的PBCT高剂量组(n = 50)。为比较HrQoL,将来自普通人群的男性作为对照组(称为“标准组”)。统计学显著性水平设定为P < 0.05,就测试HrQoL差异而言,临床重要性定义为Δ≥2.5分。

结果

与仅接受手术的TCSs相比,接受PBCT的TCSs报告出现典型AHOs的人数更多。在接受PBCT高剂量治疗的TCSs中观察到最高的发生率。此外,在16年的观察期内,除雷诺现象外,描述典型AHOs的TCSs数量有所增加。在最后一次SW时,PBCT高剂量组报告的AHOs(任何类型)中位数为4个,而仅手术组或PBCT标准组后为2个。以仅手术组为参照,在最后一次SW时,PBCT高剂量组而非PBCT标准组与身体HrQoL下降相关(A2回归系数:-4.3;P = 0.008)。当将所有TCSs与标准组进行比较时,在任何一次SW时,身体和心理HrQoL均未观察到具有临床重要意义的差异。然而,在最后一次SW时,接受PBCT高剂量治疗后的TCSs代表了一组HrQoL受到临床重要损害的TCSs。在典型AHOs中,只有PSN降低了HrQoL。慢性疲劳、疼痛、焦虑/抑郁、性功能障碍、失业、单身和低教育程度是其他协变量。

结论

在治疗后的中位数28年后,发现TCSs的HrQoL与标准组相当。即使AHOs,尤其是PBCT高剂量治疗后,在TCSs中变得更加普遍,这种相似性仍然成立。该研究表明,有PBCT高剂量治疗史的个体经历长期AHOs发生率显著增加的风险很高,这随后导致HrQoL下降。在终身随访护理期间识别并对这些TCSs给予专门关注至关重要。

相似文献

1
Adverse health outcomes and global quality of life in long-term testicular cancer survivors: a longitudinal 30-year perspective.长期睾丸癌幸存者的不良健康结局与全球生活质量:30年纵向研究视角
Ann Oncol. 2023 Dec;34(12):1165-1174. doi: 10.1016/j.annonc.2023.09.3101. Epub 2023 Sep 21.
2
Mortality and Second Cancer Incidence After Treatment for Testicular Cancer: Psychosocial Health and Lifestyle Are Modifiable Prognostic Factors.睾丸癌治疗后的死亡率和第二癌症发生率:心理社会健康和生活方式是可改变的预后因素。
J Clin Oncol. 2022 Aug 10;40(23):2588-2599. doi: 10.1200/JCO.21.02105. Epub 2022 Apr 5.
3
Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.北美睾丸癌幸存者接受现代顺铂化疗后不良健康结局的多机构评估
J Clin Oncol. 2017 Apr 10;35(11):1211-1222. doi: 10.1200/JCO.2016.70.3108. Epub 2017 Feb 27.
4
Risk of positive selection bias in longitudinal surveys among cancer survivors: Lessons learnt from the national Norwegian Testicular Cancer Survivor Study.癌症幸存者纵向研究中阳性选择偏倚的风险:来自挪威全国睾丸癌幸存者研究的经验教训。
Cancer Epidemiol. 2020 Aug;67:101744. doi: 10.1016/j.canep.2020.101744. Epub 2020 Jul 9.
5
Use of Medications for Treating Anxiety or Depression among Testicular Cancer Survivors: A Multi-Institutional Study.应用药物治疗睾丸癌幸存者的焦虑或抑郁:一项多机构研究。
Cancer Epidemiol Biomarkers Prev. 2021 Jun;30(6):1129-1138. doi: 10.1158/1055-9965.EPI-20-1762. Epub 2021 Apr 13.
6
Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.基于顺铂的标准化疗后睾丸癌幸存者的累积发病率负担:一项多机构研究。
J Clin Oncol. 2018 May 20;36(15):1505-1512. doi: 10.1200/JCO.2017.77.0735. Epub 2018 Apr 4.
7
Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors.睾丸癌幸存者中顺铂相关不良健康结局与残疾和失业的关系。
JNCI Cancer Spectr. 2020 Mar 20;4(4):pkaa022. doi: 10.1093/jncics/pkaa022. eCollection 2020 Aug.
8
Thyroid hypofunction in aging testicular cancer survivors.衰老的睾丸癌幸存者甲状腺功能减退。
Acta Oncol. 2021 Nov;60(11):1452-1458. doi: 10.1080/0284186X.2021.1958004. Epub 2021 Aug 5.
9
The personality trait of neuroticism is strongly associated with long-term morbidity in testicular cancer survivors.神经质的人格特质与睾丸癌幸存者的长期发病密切相关。
Acta Oncol. 2009;48(6):842-9. doi: 10.1080/02841860902795232.
10
Adverse Health Outcomes and Associations with Self-Reported General Health in Childhood Lymphoma Survivors.儿童淋巴瘤幸存者的不良健康结局及其与自我报告的总体健康状况的关联
J Adolesc Young Adult Oncol. 2017 Sep;6(3):470-476. doi: 10.1089/jayao.2017.0018. Epub 2017 Aug 24.

引用本文的文献

1
A study of subjective memory impairment in long-term testicular cancer survivors.一项关于长期睾丸癌幸存者主观记忆障碍的研究。
Br J Cancer. 2025 Jul 10. doi: 10.1038/s41416-025-03108-z.
2
Patient-reported outcomes (PROs) in clinical trials and in clinical practice: report from the XXI national conference of the Italian Association of Medical Oncology (AIOM).临床试验和临床实践中的患者报告结局(PROs):来自意大利医学肿瘤学会(AIOM)第21届全国会议的报告
BMJ Oncol. 2025 Jun 17;4(1):e000783. doi: 10.1136/bmjonc-2025-000783. eCollection 2025.
3
Feasibility and Oncological Safety of Robotic Retroperitoneal Lymph Node Dissection in Patients with Testicular Cancer-Single-Center Experience.
睾丸癌患者机器人腹膜后淋巴结清扫术的可行性及肿瘤学安全性——单中心经验
Cancers (Basel). 2025 Apr 25;17(9):1439. doi: 10.3390/cancers17091439.
4
Cost-effectiveness of de-escalated molecular subtype dependent use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer in a Swedish setting.瑞典背景下,肌肉浸润性膀胱癌患者新辅助化疗依分子亚型降阶梯使用的成本效益分析
Front Oncol. 2025 Apr 2;15:1556881. doi: 10.3389/fonc.2025.1556881. eCollection 2025.
5
Biochemical Hypogonadism in Aging Testicular Cancer Survivors: A Clinical Challenge.老年睾丸癌幸存者的生化性腺功能减退:一项临床挑战。
Eur Urol Open Sci. 2025 Jan 17;72:10-16. doi: 10.1016/j.euros.2024.12.010. eCollection 2025 Feb.
6
Assessing quality of life in childhood cancer survivors at risk for hearing loss: a comparison of HEAR-QL and PROMIS measures.评估有听力损失风险的儿童癌症幸存者的生活质量:HEAR-QL与患者报告结果测量信息系统(PROMIS)量表的比较
Front Oncol. 2024 Mar 6;14:1362315. doi: 10.3389/fonc.2024.1362315. eCollection 2024.